Abstract
Translational research on complex, multifactorial mental health disorders, such as bipolar disorder, major depressive disorder, schizophrenia, and substance use disorders requires databases with large-scale, harmonized, and integrated real-world and research data.
The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was established in 2019 to collect, store, connect, and supply such high-quality phenotypic data and biospecimens from patients and study participants, including healthy controls, recruited at the Department of Psychiatry and Psychotherapy and the Institute of Psychiatric Phenomics and Genomics, University Hospital of the Ludwig-Maximilians-University (LMU), Munich, Germany. Participants are asked to complete a questionnaire that assesses sociodemographic and cross-diagnostic clinical information, provide blood samples, and grant access to their existing medical records. The generated data and biosamples are available to both academic and industry researchers. In the current manuscript, we outline the workflow and infrastructure of the MMHB, describe the clinical characteristics and representativeness of the sample collected so far, and reveal future plans for expansion and application.
As of October 31, 2021, the MMHB contains a continuously growing set of data from 578 patients and 104 healthy controls (46.37% female; median age, 38.31 years). The five most common mental health diagnoses in the MMHB are recurrent depressive disorder (38.78%; ICD-10: F33), alcohol-related disorders (19.88%; ICD-10: F10), schizophrenia (19.69%; ICD-10: F20), depressive episode (15.94%; ICD-10: F32), and personality disorders (13.78%; ICD-10: F60). Compared with the average patient treated at the recruiting hospitals, MMHB participants have significantly more mental health-related contacts, less severe symptoms, and a higher level of functioning. The distribution of diagnoses is also markedly different in MMHB participants compared with individuals who did not participate in the biobank.
After establishing the necessary infrastructure and initiating recruitment, the major tasks for the next phase of the MMHB project are to improve the pace of participant enrollment, diversify the sociodemographic and diagnostic characteristics of the sample, and improve the utilization of real-world data generated in routine clinical practice.
Competing Interest Statement
R.M. has received speakers honoraria from Otsuka Pharmaceuticals. He serves or has served as PI in clinical trials sponsored by Abide Therapeutics (Lundbeck), Bohringer-Ingelheim, Emalex Biosciences, Oryzon, Otsuka Pharmaceuticals.
F.P. is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc.
Funding Statement
C.F.W., A.N., and N.S. were supported by the DFG (German Research Council) (grant numbers: FA 876/3-1; 876/5-1). U.H. was supported by European Unions Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151). D.L. was supported by the Deutsche Forschungsgemeinschaft, Emmy Noether fellowship (LA4126/1-1) E.C.S. was supported by the Munich Clinician Scientist Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Faculty of Medicine LMU Munich gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding C.F.W., A.N., and N.S. were supported by the DFG (German Research Council) (grant numbers: FA 876/3-1; 876/5-1).
U.H. was supported by European Union’s Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151).
D.L. was supported by the Deutsche Forschungsgemeinschaft, Emmy Noether fellowship (LA4126/1-1)
E.C.S. was supported by the Munich Clinician Scientist Program.
Conflicts of Interest R.M. has received speakers honoraria from Otsuka Pharmaceuticals. He serves or has served as PI in clinical trials sponsored by Abide Therapeutics (Lundbeck), Böhringer-Ingelheim, Emalex Biosciences, Oryzon, Otsuka Pharmaceuticals.
F.P. is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker’s honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc.
Data Availability
All data stored in the Munich Mental Health Biobank are available upon reasonable request to the authors.
